STAA
$17.85
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Recent News
Alcon abandons effort to purchase LENSAR after FTC scrutiny
The Federal Trade Commission said the transaction had threatened to raise prices and stifle innovation for cataract laser eye surgery systems.
1 Russell 2000 Stock to Target This Week and 2 We Question
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
STAAR Surgical Company Q4 2025 Earnings Call Summary
Moby summary of STAAR Surgical Company's Q4 2025 earnings call
Staar Surgical Co (STAA) Q4 2025 Earnings Call Highlights: Strong Sales Growth in China and ...
Despite challenges from a terminated merger and inventory issues, Staar Surgical Co (STAA) reports significant sales growth in China and a notable improvement in gross profit margins.
STAAR Surgical Q4 Earnings Call Highlights
STAAR Surgical (NASDAQ:STAA) executives emphasized a return to execution in fiscal 2026 after what they described as a disruptive and transitional 2025, highlighting progress in China channel inventory normalization, a sharpened cost structure, and early momentum for new products including EVO+ in C